After much deliberation, this week a panel of experts advising the Food and Drug Administration voted against the approval of therapy-guided MDMA for treating PSTD.

Kennedy criticizes the panel for prohibiting PSTD patients from getting effective treatment and highlights the success of studies and clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the high improvement rates reported by participants.

Follow Kennedy on Twitter: @KennedyNation

Kennedy Now Available on YouTube: https://bit.ly/4311mhD.

Learn more about your ad choices. Visit podcastchoices.com/adchoices